Oral Rapamycin After Coronary Bare-Metal Stent Implantation to Prevent Restenosis: The Prospective, Randomized Oral Rapamycin in Argentina (ORAR II) Study
- 18 April 2006
- journal article
- research article
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 47 (8) , 1522-1529
- https://doi.org/10.1016/j.jacc.2005.12.052
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Role of oral rapamycin to prevent restenosis in patients with de novo lesions undergoing coronary stenting: results of the Argentina single centre study (ORAR trial)Heart, 2005
- Localized Hypersensitivity and Late Coronary Thrombosis Secondary to a Sirolimus-Eluting StentCirculation, 2004
- Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary ArteryNew England Journal of Medicine, 2003
- Randomized Study to Assess the Effectiveness of Slow- and Moderate-Release Polymer-Based Paclitaxel-Eluting Stents for Coronary Artery LesionsCirculation, 2003
- Oral Everolimus Inhibits In-Stent Neointimal GrowthCirculation, 2002
- SIROLIMUS (RAPAMYCIN)-BASED THERAPY IN HUMAN RENAL TRANSPLANTATIONTransplantation, 1999
- Time course and mechanism of early luminal diameter loss after percutaneous transluminal coronary angioplastyThe American Journal of Cardiology, 1995
- Early decrease in minimal luminal diameter after successful percutaneous transluminal coronary angioplasty predicts late restenosisThe American Journal of Cardiology, 1993
- Serial angiographic follow-up after palmaz-schatz stent implantation: Comparison with conventional balloon angioplastyJournal of the American College of Cardiology, 1993
- Quantitative angiographic assessment of elastic recoil after percutaneous transluminal coronary angioplastyThe American Journal of Cardiology, 1990